Malondialdehyde in benign prostate hypertrophy: a useful marker?
Open Access
- 1 January 2003
- journal article
- Published by Wiley in Mediators of Inflammation
- Vol. 12 (2) , 127-128
Abstract
Benign prostate hypertrophy (BPH) is the most common benign tumor in men due to obstruction of the urethra and, finally, uremia. Malondialdehyde (MDA) is a product derived from peroxidation of polyunsaturated fatty acids and related esters. Evaluation of MDA in serum represents a non‐invasive biomarker of oxidative stress. Prostate‐specific antigen (PSA) is a sensitive marker for prostatic hypertrophy and cancer. We analyzed MDA serum levels to evaluate the oxidative stress in BPH. To this end, 22 BPH patients and 22 healthy donors were enrolled. Data show an increase of MDA level in BPH patients and a positive correlation between PSA and MDA levels. In conclusion, we describe a previously unknown relationship between PSA and MDA as an index of inflammation and oxidative stress in BPH.Keywords
Funding Information
- University of Messina Medical School
This publication has 4 references indexed in Scilit:
- The role of apoptosis in aging and age-related disease: updateZeitschrift für Gerontologie und Geriatrie, 2001
- Indices of lipid peroxidation in vivo: strengths and limitationsFree Radical Biology and Medicine, 2000
- Diseases of agingVaccine, 2000
- [Prostate-specific antigen in prostatic pathology].1988